Related Experiment Video
Updated: Jun 9, 2025
High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
Published on: March 24, 2015
Inhibiting the P2Y12 Receptor in Megakaryocytes and Platelets Suppresses Interferon-Associated Responses
Marcin A Sowa1, Haoyu Sun1, Tricia T Wang1
1Department of Medicine, New York University Grossman School of Medicine, New York, New York, USA.
Abstract:
The authors investigated the impact of antiplatelet therapy on the megakaryocyte (MK) and platelet transcriptome. RNA-sequencing was performed on MKs treated with aspirin or P2Y12 inhibitor, platelets from healthy volunteers receiving aspirin or P2Y12 inhibition, and platelets from patients with systemic lupus erythematosus (SLE). P2Y12 inhibition reduced gene expression and inflammatory pathways in MKs and platelets. In SLE, the interferon (IFN) pathway was elevated. In vitro experiments demonstrated the role of P2Y12 inhibition in reducing IFNα-induced platelet-leukocyte interactions and IFN signaling pathways. These results suggest that P2Y12 inhibition may have therapeutic potential for proinflammatory and autoimmune conditions like SLE.
Insights
Antiplatelet therapy, specifically P2Y12 inhibition, impacts megakaryocyte and platelet gene expression. P2Y12 inhibitors may offer therapeutic benefits for autoimmune diseases like systemic lupus erythematosus (SLE).
Area of Science:
- Hematology
- Immunology
- Pharmacology
Background:
- Antiplatelet therapies are crucial in cardiovascular disease management.
- Megakaryocytes (MKs) and platelets play roles beyond hemostasis, including inflammation.
- Systemic lupus erythematosus (SLE) involves dysregulated immune responses and inflammation.
Purpose of the Study:
- To investigate the impact of antiplatelet therapy on the megakaryocyte and platelet transcriptome.
- To explore the potential of P2Y12 inhibition in modulating inflammatory pathways in platelets.
- To assess the therapeutic potential of P2Y12 inhibition in autoimmune conditions like SLE.
Main Methods:
- RNA-sequencing of MKs and platelets from healthy volunteers and SLE patients.
- Treatment of MKs with aspirin or P2Y12 inhibitors.
- In vitro experiments assessing P2Y12 inhibition's effect on interferon-induced pathways.
Main Results:
- P2Y12 inhibition significantly reduced gene expression and inflammatory pathways in MKs and platelets.
- Elevated interferon (IFN) signaling pathways were observed in platelets from SLE patients.
- P2Y12 inhibition attenuated IFNα-induced platelet-leukocyte interactions and IFN signaling.
Conclusions:
- P2Y12 inhibition alters the transcriptome of MKs and platelets, reducing inflammatory signatures.
- Platelet P2Y12 inhibition demonstrates potential in mitigating pro-inflammatory and autoimmune responses.
- P2Y12 inhibitors may represent a novel therapeutic strategy for conditions like SLE.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:29Immune Response Against Viral Pathogens
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
01:18Structure and Function of Platelets
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
01:20The JAK-STAT Signaling Pathway